Abstract
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have